کد مقاله | کد نشریه | سال انتشار | مقاله انگلیسی | نسخه تمام متن |
---|---|---|---|---|
10143099 | 1646141 | 2018 | 10 صفحه PDF | دانلود رایگان |
عنوان انگلیسی مقاله ISI
The influence of maintenance therapy of rituximab on the survival of elderly patients with follicular lymphoma. A retrospective analysis from the database of the Czech Lymphoma Study Group
ترجمه فارسی عنوان
تأثیر درمان نگهدارنده ریتوکسیماب بر بقای بیماران سالمند مبتلا به لنفوم فولیکولار. تجزیه و تحلیل گذشته نگر از پایگاه داده گروه مطالعه لنفوم چک
دانلود مقاله + سفارش ترجمه
دانلود مقاله ISI انگلیسی
رایگان برای ایرانیان
کلمات کلیدی
لنفوم فولیکولار، بیماران سالمند، ریتوکسیماب، ایمونو شیمیایی، نگهداری، بقا،
موضوعات مرتبط
علوم زیستی و بیوفناوری
بیوشیمی، ژنتیک و زیست شناسی مولکولی
تحقیقات سرطان
چکیده انگلیسی
The rituximab maintenance (RM) therapy for follicular lymphoma is effective and clinically well tolerated, however there is limited data regarding this from the elderly segment of the population. This analysis was performed to evaluate the efficacy of RM in elderly patients 65âyears of age and older and to assess the influence of the induction therapy with immunochemotherapy (R-CHEMO) on the treatment outcome in a real world setting. A total of 232 consecutive patients treated with first-line R-CHEMO and RM (RM1 group; nâ=â158) or observation (RM0 group; nâ=â74) were analyzed. The effect of which induction therapy (R-CHOP vs. R-CVP) and the response of the patients to the first-line therapy were also evaluated. The addition of RM improved the treatment results in elderly patients. The 5- year overall survival rate in patients receiving R-CHEMOâ+âRM1 compared to patients receiving R-CHEMOâ+âRM0, was 83.7% (95% CI 76.1-89%) and 64.3% (95% CI 51.8-74.3%), respectively, pâ=â0.0012. The induction therapy with R-CHOP was found to be more effective than R-CVP but it is necessary to point out higher age of patients in the R-CVP arm. The 5- year overall survival rate in patients using R-CHOPâ±âRM and R-CVPâ±âRM was 84.9% (95% CI 77.5-90%), and 65.0% (95% CI 50.1-76.4%), respectively, pâ=â0.0008. The patients who achieved CRâ+âuCR after having received first-line therapy had better outcomes compared to patients in PR. The 5- year overall survival rate in uCRâ+âCR patients treated with R-CHEMOâ+âRM1 and PR patients treated with R-CHEMOâ+âRM1 was 90.6% and 68.3%, respectively, pâ=â0.0019. Rituximab maintenance treatment in patients 65âyears and older yielded improved survival rates in a real world clinical setting. The R-CHOP regimen seems to be a more effective induction agent than R-CVP but the outcome of less intensively treated patients with R-CVPâ+âRM is also acceptable. The achievement of uCRâ+âCR after first-line therapy is associated with a better outcome.
ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: Leukemia Research - Volume 73, October 2018, Pages 29-38
Journal: Leukemia Research - Volume 73, October 2018, Pages 29-38
نویسندگان
David Belada, Vit Prochazka, Andrea Janikova, Vit Campr, Petra Blahovcova, Robert Pytlik, Alice Sykorova, Pavel Klener, Katerina Benesova, Jan Pirnos, Juraj Duras, Heidi Mocikova, Marek Trneny,